atai Life Sciences Increases Ownership Position In COMPASS Pathways Based On Positive Clinical Trial Outcomes Of Psilocybin-Based Treatment For Resistant Major Depression

Based on the outcomes of a phase 2b clinical trial conducted by COMPASS Pathways on a psilocybin-based medication for treatment-resistant depression (TRD), atai Life Sciences, a clinical-stage biopharmaceutical company, increased its ownership position in COMPASS Pathways from 19.4% to 20.8%. This new investment increases atai’s position as COMPASS’ largest shareholder.

The compound is currently referred to as COMP360 psilocybin. The clinical trial included 233 people with TRD who had previously failed to respond to treatment with at least two and up to four antidepressants. The trial took place across 22 sites; it was structured . . .